Blackstone Commits $750 Million to Johnson & Johnson's Phase 3 Trials of Retinal Disease Drug OLN324
- Blackstone Life Sciences funds will provide $750 million to Johnson & Johnson for Phase 3 development of investigational retinal disease treatment OLN324.
- The clinical program will target wet age-related macular degeneration and diabetic macular edema.
- Early clinical results were described as encouraging; the planned Phase 3 program will further evaluate the treatment.
- Funding is contingent on Johnson & Johnson closing its acquisition of Ollin Biosciences.
- The investment entitles Blackstone to regulatory and sales milestone payments, as well as single-digit royalties.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Blackstone Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20261115269157) on November 16, 2026, and is solely responsible for the information contained therein.